Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NewAmsterdam Pharma Company N.V. - Ordinary Shares (NQ:NAMS)

19.27 +0.35 (+1.85%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
7 Analysts Have This To Say About NewAmsterdam Pharma
Via Benzinga
Deep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)
Via Benzinga
NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
Presentations include new data from BROADWAY and TANDEM Phase 3 clinical trials, demonstrating obicetrapib’s impact on key lipid and lipoprotein biomarkers 
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Where NewAmsterdam Pharma Stands With Analysts
Via Benzinga
The Analyst Verdict: NewAmsterdam Pharma Co In The Eyes Of 6 Experts
Via Benzinga
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
The company unveiled promising results for its experimental cholesterol treatment, a daily pill that blocks PCSK9. 
Via Investor's Business Daily
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?
These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN. 
Via Benzinga
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95. 
Via Investor's Business Daily
Top 3 Health Care Stocks That May Collapse This Quarter
Via Benzinga
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?
NewAmsterdam Pharma reports Phase 3 trial success for obicetrapib, achieving significant LDL-C reduction in ASCVD and HeFH patients on standard therapy. 
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.